GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Karo Pharma AB (OTCPK:KARBF) » Definitions » Cash Flow from Investing

Karo Pharma AB (Karo Pharma AB) Cash Flow from Investing : $-98.1 Mil (TTM As of Jun. 2022)


View and export this data going back to . Start your Free Trial

What is Karo Pharma AB Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Jun. 2022, Karo Pharma AB spent $0.0 Mil on purchasing property, plant, equipment. It gained $0.0 Mil from selling property, plant, and equipment. It spent $0.0 Mil on purchasing business. It gained $0.0 Mil from selling business. It spent $0.0 Mil on purchasing investments. It gained $0.0 Mil from selling investments. It paid $0.0Mil for net Intangibles purchase and sale. And it paid $0.0 Mil for other investing activities. In all, Karo Pharma AB gained $0.0 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Jun. 2022.


Karo Pharma AB Cash Flow from Investing Historical Data

The historical data trend for Karo Pharma AB's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karo Pharma AB Cash Flow from Investing Chart

Karo Pharma AB Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -148.44 -298.12 -258.86 -184.66 -90.51

Karo Pharma AB Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Jun22
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.24 -103.51 7.86 -1.19 -

Karo Pharma AB Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Karo Pharma AB's Cash Flow from Investing for the fiscal year that ended in Dec. 2021 is calculated as:

Karo Pharma AB's Cash Flow from Investing for the quarter that ended in Jun. 2022 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-98.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Karo Pharma AB  (OTCPK:KARBF) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Karo Pharma AB's purchase of property, plant, equipment for the three months ended in Jun. 2022 was $0.0 Mil. It means Karo Pharma AB spent $0.0 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Karo Pharma AB's sale of property, plant, equipment for the three months ended in Jun. 2022 was $0.0 Mil. It means Karo Pharma AB gained $0.0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Karo Pharma AB's purchase of business for the three months ended in Jun. 2022 was $0.0 Mil. It means Karo Pharma AB spent $0.0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Karo Pharma AB's sale of business for the three months ended in Jun. 2022 was $0.0 Mil. It means Karo Pharma AB gained $0.0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Karo Pharma AB's purchase of investment for the three months ended in Jun. 2022 was $0.0 Mil. It means Karo Pharma AB spent {stock_data.stock.currency_symbol}}0.0 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Karo Pharma AB's sale of investment for the three months ended in Jun. 2022 was $0.0 Mil. It means Karo Pharma AB gained $0.0 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Karo Pharma AB's net Intangibles purchase and sale for the three months ended in Jun. 2022 was $0.0 Mil. It means Karo Pharma AB paid $0.0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Karo Pharma AB's cash from discontinued investing activities for the three months ended in Jun. 2022 was 0.0 Mil. It means Karo Pharma AB paid $0.0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Karo Pharma AB's cash from other investing activities for the three months ended in Jun. 2022 was $0.0 Mil. It means Karo Pharma AB paid $0.0 Mil for other investing activities.


Karo Pharma AB Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Karo Pharma AB's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Karo Pharma AB (Karo Pharma AB) Business Description

Traded in Other Exchanges
N/A
Address
Klara Norra Kyrkogata 33, Stockholm, SWE, 111 22
Karo Pharma AB is a healthcare corporation. It is engaged in the business activity of developing and marketing products to pharmacies and directly to the healthcare sector. The trademarks of the firm are Ibux, Paracet, Dosett, Allevo, and Swereco. It operates in the segment of development and sale of products to pharmacies, digital distribution channels and food stores. The company carries its business operations in Sweden and internationally, of which the majority of the revenue is generated from Sweden and Norway.

Karo Pharma AB (Karo Pharma AB) Headlines

From GuruFocus

Avista Capital Partners To Sell Trimb To Karo Pharma

By PRNewswire PRNewswire 06-25-2019